Antibody Classification via Flow Cytometry Reactivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for obtaining and identifying antibodies specific to cancer cell surface antigens are labor-intensive, time-consuming, and costly, and often include unnecessary antibodies with insufficient affinity and reactivity, hindering their effective use in medical and research fields.
Innovation Solution
A method involving the preparation of cell lines expressing cell surface antigens, reacting antibodies with these cell lines, and using flow cytometry analysis to classify antibodies based on reactivity, allowing for rapid identification of antigens and selection of clinically applicable antibodies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If current methods are used to obtain and identify antibodies specific to cancer cell surface antigens, then antibodies can be obtained, but the process is labor-intensive, time-consuming, and costly
Solution Approach 1:
The patent segments the antibody identification process into distinct classification stages based on reactivity patterns. Antibodies are grouped into families and subfamilies according to their binding characteristics to cell surface antigens, allowing parallel processing and systematic identification rather than individual assessment of each antibody.
Solution Approach 2:
The patent performs preliminary classification of antibodies based on their reactivity to cell lines expressing specific cell surface antigens before detailed identification. This preliminary grouping based on flow cytometry data allows researchers to focus subsequent detailed analysis only on promising antibody candidates, reducing overall time and resource requirements.
2Productivity
If current methods are used to obtain and identify antibodies specific to cancer cell surface antigens, then antibodies can be obtained, but the process is labor-intensive and costly
Solution Approach 1:
The patent divides the complex antibody identification process into manageable segments: initial reactivity assessment, classification into families based on shared reactivity patterns, and detailed characterization of representative antibodies. This segmentation reduces the apparent complexity by breaking down the overwhelming task of individual antibody analysis into systematic, repeatable steps.
Solution Approach 2:
The patent uses cell lines expressing cell surface antigens as standardized models to represent different antigen types. By testing antibodies against these standardized cell line copies rather than directly against diverse primary cells or tissues, the process becomes more systematic, reproducible, and less labor-intensive.
3Quantity of substance
If current methods are used to obtain antibodies, then a large number of antibodies can be obtained, but many are unnecessary with insufficient affinity and reactivity
Solution Approach 1:
The patent performs preliminary classification based on reactivity to cell lines expressing cell surface antigens before final antibody selection. This preliminary filtering based on flow cytometry data allows researchers to identify and focus on high-quality antibody candidates with proven affinity and reactivity, eliminating unnecessary antibodies early in the process.
Solution Approach 2:
The patent uses cell lines as standardized models to systematically assess antibody quality. By testing against these controlled cellular models with known antigen expression, the patent enables objective comparison of antibody affinity and reactivity, ensuring that only antibodies meeting quality criteria are advanced for further use.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the rapid classification and identification of antibodies, facilitating their use in cancer diagnosis and treatment while minimizing unnecessary antibodies, thus improving efficiency and reducing costs.
Implementation Method 1
analyzing each cell after step (2) by flow cytometry so as to obtain data showing reactivity between the antibody and the cell surface
Data Source
AI summary
The present invention relates to an isolated antibody against HER1, an isolated antibody against CD147, an isolated antibody against CD73, and an isolated antibody against EpCAM; reagents and compositions including said antibodies; and uses of said reagents, compositions, and antibodies. The present invention also relates to nucleic acids and vectors expressing said antibodies. The invention further relates to transformants comprising said nucleic acids or vectors.